var data={"title":"Dapsone (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dapsone (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388150?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dapsone-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dapsone (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=dapsone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dapsone (systemic): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016738\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015321\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatitis herpetiformis:</b> Oral: Start at 50 mg daily, increase to 300 mg daily, or higher to achieve full control, reduce to minimum maintenance dosage as soon as possible </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leprosy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tuberculoid (paucibacillary): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Hansen's Disease Program: 100 mg daily in combination with rifampin for 12 months (NHDP [HRSA 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">World Health Organization: 100 mg daily in combination with rifampin for 6 months (WHO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lepromatous (multibacillary):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Hansen's Disease Program: 100 mg daily in combination with rifampin and clofazimine for 24 months (NHDP [HRSA 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">World Health Organization: 100 mg daily in combination with rifampin and clofazimine for 12 months (WHO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aphthous ulcers, severe (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 25 mg daily for 3 days; increase dose in increments of 25 mg daily every 3 days up to 100 mg daily for 3 days, then increase by 25 mg daily every 7 days up to 150 mg daily. Administer in 2 divided doses (75 mg dose is administered in 3 divided doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: 100 to 150 mg daily in 2 divided doses with or without concomitant colchicine (Lynde 2009; Rogers 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bullous systemic lupus erythematosus (off-label use):</b> Oral: 100 mg once daily with or without prednisone (Fabbri 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia (ITP) (off-label use):</b> Oral:  75 to 100 mg daily or 1 to 2 mg/kg/day; duration of therapy is &ge;21 days (Damodar 2005; Godeau 1997; Provan 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pemphigus vulgaris (off-label use):</b> Oral: 25 mg daily for 7 days, then increase dose in increments of 25 mg daily every 7 days up to 100 mg daily for 7 days (4 weeks total therapy) with concomitant prednisone. Administer in 2 divided doses (a 75 mg dose is administered in 3 divided doses) (Azizi 2008). <b>Note: </b> If patient becomes lesion free, taper and discontinue gradually by decreasing dose 25 mg daily over 7 days. If no new lesions are seen, gradual taper is continued. If lesions recur, dose is increased by 25 mg daily at 7-day intervals until the patient develops no new lesions. Taper is usually ~4 weeks total.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Pneumocystis </i></b> <b> pneumonia (PCP) in HIV-infected patients (off-label use; HHS [OI adult 2015]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis (primary or secondary; alternative to preferred therapy): </i> 100 mg daily once daily or in 2 divided doses as monotherapy <b>or</b> 50 mg daily in combination with weekly pyrimethamine and leucovorin <b>or</b> 200 mg weekly in combination with weekly pyrimethamine and leucovorin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment (mild to moderate disease; alternative to preferred therapy):</i> 100 mg once daily in combination with trimethoprim for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Toxoplasma gondii</i> encephalitis in HIV-infected patients (alternative to preferred therapy) (off-label use):</b>  <i>Primary prophylaxis: </i> Oral: 50 mg daily, in combination with weekly pyrimethamine and leucovorin <b>or</b> 200 mg weekly in combination with weekly pyrimethamine and leucovorin (HHS [OI adult 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015320\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dapsone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dapsone (systemic): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dermatitis herpetiformis:</b> Infants, Children, and Adolescents: Oral: 0.5 to 2 mg/kg/day in 1 to 2 divided doses; maximum initial daily dose in <b>adults</b>: 50 mg/<b>day</b>; once lesions controlled, the dose may be decreased as tolerated for chronic therapy; usual range: 0.125 to 0.5 mg/kg/day (Ermacora 1986; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Leprosy:</b> Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Tuberculoid (paucibacillary):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">National Hansen's Disease Program: 1 to 2 mg/kg daily (maximum daily dose: 100 mg/day) in combination with rifampin for 12 months (NHDP [HRSA 2016]; <i>Red Book</i> [AAP] 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">World Health Organization (WHO 2012): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&lt;10 years: 2 mg/kg daily in combination with rifampin for 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&ge;10 years to &le;14 years: 50 mg daily in combination with rifampin for 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;14 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Lepromatous (multibacillary): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">National Hansen's Disease Program: 1 mg/kg daily (maximum daily dose: 100 mg/day) in combination with rifampin and clofazimine for 24 months (NHDP [HRSA 2016]; <i>Red Book</i> [AAP] 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">World Health Organization (WHO 2012): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&lt;10 years: 2 mg/kg daily in combination with rifampin and clofazimine for 12 months.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&ge;10 years to &le;14 years: 50 mg daily in combination with rifampin and clofazimine for 12 months.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;14 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Immune thrombocytopenia (off-label use):</b> Children &ge;3 years and Adolescents: Oral: 1 to 2 mg/kg/day (Damodar 2005, Meeker 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Pneumocystis</i></b> <b> pneumonia (PCP) in HIV-exposed/-positive patients (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Prophylaxis (primary or secondary; alternative to preferred therapy):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children: 2 mg/kg/day once daily (maximum dose: 100 mg daily) or 4 mg/kg/dose once weekly (maximum dose: 200 mg) (HHS [OI pediatric] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Treatment (mild to moderate disease; alternative to preferred therapy):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children: 2 mg/kg/day once daily (maximum dose: 100 mg daily) in combination with trimethoprim for 21 days (HHS [OI pediatric] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Toxoplasma gondii</i> encephalitis in HIV-exposed/-positive patients (alternative to preferred therapy) (off-label use):</b> <i>Primary prophylaxis:</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: 2 mg/kg/dose or 15 mg/m<sup>2</sup>/dose once daily (maximum daily dose: 25 mg/day), in combination with pyrimethamine and leucovorin (HHS [OI pediatric] 2015) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents (mild to moderate disease): Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015322\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015323\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary (Legendre 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46564750\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution (Legendre 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015379\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9490508\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015365\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Oral: Administer with meals if GI upset occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015286\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of leprosy (due to susceptible strains of <i>Mycobacterium leprae</i>) and dermatitis herpetiformis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475193\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Aphthous ulcers (severe); Bullous systemic lupus erythematosus; Immune thrombocytopenia (adults); immune thrombocytopenia (children/adolescents); Pemphigus vulgaris (oral); Pneumocystis pneumonia (PCP) prophylaxis in HIV-infected patients (adolescents and adults); Pneumocystis pneumonia (PCP) prophylaxis in HIV-infected patients (children); Pneumocystis pneumonia (PCP) treatment in HIV-infected patients (adolescents and adults); Pneumocystis pneumonia (PCP) treatment in HIV-infected patients (children); Relapsing polychondritis; Toxoplasma gondii encephalitis prophylaxis in HIV-infected patients (adolescents and adults); Toxoplasma gondii encephalitis prophylaxis in HIV-infected patients (children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015264\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dapsone may be confused with Diprosone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015297\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Hematologic: Reticulocyte increase (2% to 12%), hemolysis (&gt;10%; dose related; seen in patients with and without G6PD deficiency), hemoglobin decrease (&gt;10%; 1-2 g/dL; almost all patients),  methemoglobinemia (&gt;10%), red cell life span shortened (&gt;10%), Agranulocytosis, anemia, leukopenia, pure red cell aplasia (case report)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fever, headache, insomnia, psychosis, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Bullous and exfoliative dermatitis, erythema nodosum, exfoliative dermatitis, morbilliform and scarlatiniform reactions, phototoxicity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoalbuminemia (without proteinuria), male infertility</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Lower motor neuron toxicity (prolonged therapy), lupus-like syndrome, peripheral neuropathy (rare, nonleprosy patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocular:  Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Albuminuria, nephrotic syndrome, renal papillary necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Interstitial pneumonitis, pulmonary eosinophilia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Infectious mononucleosis-like syndrome (rash, fever, lymphadenopathy, hepatic dysfunction)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015294\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dapsone or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015295\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: Aplastic anemia, agranulocytosis and other severe blood dyscrasias (some fatal) have been reported; monitor for signs/symptoms (eg, fever, sore throat, pallor, purpura, jaundice). Closely monitor CBC and discontinue therapy if a significant reduction in leukocytes, platelets, or hemopoiesis is seen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic reactions: Serious dermatologic reactions, including toxic erythema, erythema multiforme, toxic epidermal necrolysis, morbilliform and scarlatiniform reactions, urticaria, and erythema nodosum have been reported rarely. Discontinue therapy if new or severe dermatologic reactions occur; leprosy reactional states (eg, erythema nodosum leprosum) do not require discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Toxic hepatitis and cholestatic jaundice have been reported; hyperbilirubinemia may occur more frequently in G6PD deficient patients. Monitor liver function; discontinue use if abnormalities occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral neuropathy: Motor loss and muscle weakness have been reported; discontinue use if symptoms of peripheral neuropathy develop. Recovery after discontinuation is usually complete; some patients may tolerate retreatment at reduced doses. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide allergy: Use with caution in patients with hypersensitivity to other sulfonamides; sulfone reactions may also occur as potentially fatal hypersensitivity reactions, requiring drug discontinuation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia: Use with caution in patients with severe anemia; treat prior to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; dose-related hemolysis and methemoglobinemia may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemoglobin M deficiency: Use with caution in patients with hemoglobin M deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobin reductase deficiency: Use with caution in patients with methemoglobin reductase deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015301\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (major), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015302\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9096&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions. Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Dapsone (Systemic) may enhance the adverse/toxic effect of Atazanavir. Specifically, the risk of hyperbilirubinemia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: May decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015289\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015290\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Dapsone crosses the placenta (Brabin 2004). Per the manufacturer, dapsone has not shown an increased risk of congenital anomalies when given during all trimesters of pregnancy. Several reports have described adverse effects in the newborn after in utero exposure to dapsone, including neonatal hemolytic disease, methemoglobinemia, and hyperbilirubinemia (Hocking 1968; Kabra 1998; Thornton 1989). Dapsone may be used in pregnant women requiring maintenance therapy of either leprosy or dermatitis herpetiformis. Dapsone may be used as an alternative agent for management of <i>Pneumocystis jirovecii</i> pneumonia (PCP) or <i>Toxoplasma gondii</i> encephalitis in pregnant, HIV-infected patients (HHS [OI Adult] 2016). Because of the theoretical increased risk for hyperbilirubinemia and kernicterus, neonatal care providers should be informed if maternal dapsone is used near term (HHS [OI Adult] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015293\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Dapsone is excreted in breast milk and can be detected in the serum of nursing infants. Hemolytic anemia has been reported in a breast-fed infant (Sanders 1982). Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015367\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Check G6PD levels (prior to initiation); CBC (weekly for first month, monthly for 6 months and semiannually thereafter); reticulocyte counts; liver function tests (baseline and periodic). Monitor patients for signs of jaundice, hemolysis, and blood dyscrasias. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015309\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive antagonist of para-aminobenzoic acid (PABA) and prevents normal bacterial utilization of PABA for the synthesis of folic acid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015311\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and almost complete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Dapsone: 70% to 90%; Metabolite: ~99% (Zuidema 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.5 L/kg (Zuidema 1986) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (acetylation and hydroxylation); forms multiple metabolites (Zuidema 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children: 15.1 hours (Mirochnick 1993); Adults: 28 hours (range: 10 to 50 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~85% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322077\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dapsone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $73.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $90.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390227\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Daps (AR);</li>\n      <li>Dapsomed (BD);</li>\n      <li>Dapson (DK, EG, KR, NL, NO);</li>\n      <li>Dapson-Fatol (DE);</li>\n      <li>Dapsona (CO, CU);</li>\n      <li>Dapsone (AU);</li>\n      <li>Disulone (FR);</li>\n      <li>Dopsan (TH);</li>\n      <li>Lennon-Dapsone (ZA);</li>\n      <li>Lepsone (BD);</li>\n      <li>Pyrisone (SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aczone prescribing information, Allergan, Inc, Irvine CA, February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds; <i>Red Book: 2015 Report of the Committee on Infectious Diseases.</i> 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23285328\"></a>Azizi A and Lawaf S, &ldquo;The Management of Oral Pemphigus Vulgaris With Systemic Corticosteroids and Dapsone,&rdquo; Journal Of Dental Research, Dental Clinics, And Dental Prospects, 2008, 2(1):33-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/23285328/pubmed\" target=\"_blank\" id=\"23285328\">23285328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borras-Blasco J, Conesa-Garcia V, Navarro-Ruiz A, et al, &quot;Pure Red Cell Aplasia Associated With Dapsone Therapy,&quot; <i>Ann Pharmacother</i>, 2005, 39(6):1137-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/15870135/pubmed\" target=\"_blank\" id=\"15870135\">15870135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brabin BJ, Eggelte TA, Parise M, Verhoeff F. Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes. <i>Drug Saf</i>. 2004;27(9):633-648.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/15230645/pubmed\" target=\"_blank\" id=\"15230645\">15230645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"449538\"></a>Damiani JM, Levine HL. Relapsing polychondritis- report of ten cases. <i>Laryngoscope.</i> 1979;89:929-946.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/449538/pubmed\" target=\"_blank\" id=\"449538\">449538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dapsone [prescribing information]. Princeton, NJ: Jacobus Pharmaceutical Co; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients. <i>Eur J Haematol</i>. 2005;75(4):328-331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/16146539/pubmed\" target=\"_blank\" id=\"16146539\">16146539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    El-Sadr WM, Murphy RL, Yurik TM, et al, &ldquo;Atovaquone Compared With Dapsone for the Prevention of <i>Pneumocystis carinii</i> in Patients With HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both,&rdquo; <i>N Engl J Med</i>, 1998, 339(26):1889-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/9862944/pubmed\" target=\"_blank\" id=\"9862944\">9862944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ermacora E, Prampolini L, Tribbia G, et.al. Long-term follow-up of dermatitis herpetiformis in children. <i>J Am Acad Dermatol.</i> 1986;15:24-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/3722506/pubmed\" target=\"_blank\" id=\"3722506\">3722506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12814335\"></a>Fabbri P, Cardinali C, Giomi B, et al, &ldquo;Cutaneous Lupus Erythematosus: Diagnosis and Management,&rdquo; <i>Am J Clin Dermatol</i>, 2003, 4(7):449-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/12814335/pubmed\" target=\"_blank\" id=\"12814335\">12814335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. <i>Br J Haematol</i>. 1997;97(2):336-339.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/9163598/pubmed\" target=\"_blank\" id=\"9163598\">9163598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19824739\"></a>Gurcan HM and Ahmed AR. &ldquo;Efficacy of Dapsone in the Treatment of Pemphigus and Pemphigoid: Analysis of Current Data,&rdquo; <i>Am J Clin Dermatol</i>, 2009, 10(6):383-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/19824739/pubmed\" target=\"_blank\" id=\"19824739\">19824739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: Recommended Treatment Regimens. http://www.hansensdisease/diagnosis/recommendedtreatment.html (Accessed on March 31, 2016).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>. Updated October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hocking DR, &quot;Neonatal Haemolytic Disease Due to Dapsone,&quot;<i> Med J Aust</i>, 1968, 1(26):1130-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/4969972/pubmed\" target=\"_blank\" id=\"4969972\">4969972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kabra NS, Nanavati RN, and Srinivasan G, &quot;Neonatal Methemoglobinemia Due to Transplacental Transfer of Dapsone,&quot; <i>Indian Pediatr</i>, 1998, 35(6):553-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/10216653 /pubmed\" target=\"_blank\" id=\"10216653 \">10216653 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics.</i> 19th ed. Philadelphia, PA: Saunders Elsevier;2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legendre DP, Muzny CA, Swiatlo E. Hansen&rsquo;s disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions.<i> Pharmacotherapy.</i> 2012;32(1):27-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/22392826 /pubmed\" target=\"_blank\" id=\"22392826 \">22392826 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Letko E, Zafirakis P, Baltatzis S, et al, &ldquo;Relapsing Polychondritis: A Clinical Review,&rdquo; <i>Semin Arthritis Rheum</i>, 2002, 31(6):384-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/12077711/pubmed\" target=\"_blank\" id=\"12077711\">12077711</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19289756\"></a>Lynde CB, Bruce AJ, and Rogers RS 3rd, &ldquo;Successful Treatment of Complex Aphthosis With Colchicine and Dapsone,&rdquo; <i>Arch Derm</i>, 2009, 145(3):273-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/19289756/pubmed\" target=\"_blank\" id=\"19289756\">19289756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Medina I, Mills J, Leoung G, et al, &ldquo;Oral Therapy for <i>Pneumocystis carinii</i> Pneumonia in the Acquired Immunodeficiency Syndrome. A Controlled Trial of Trimethoprim-Sulfamethoxazole versus Trimethoprim-Dapsone,&rdquo; <i>N Engl J Med</i>, 1990, 323(12):776-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/2392131/pubmed\" target=\"_blank\" id=\"2392131\">2392131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meeker ND, Goldsby R, Terrill KR, Delaney KS, Slayton WB. Dapsone therapy for children with immune thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 2003;25(2):173-175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/12571474/pubmed\" target=\"_blank\" id=\"12571474\">12571474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mimura MA, Hirota SK, Sugaya NN, et al, &ldquo;Systemic Treatment in Severe Cases of Recurrent Aphthous Stomatitis: An Open Trial,&rdquo; <i>Clinics (Sao Paulo)</i>, 2009, 64(3):194-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/19330244/pubmed\" target=\"_blank\" id=\"19330244\">19330244</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirochnick M, Michaels M, Clarke D, et al, &ldquo;Pharmacokinetics of Dapsone in Children,&rdquo; <i>J Pediatr</i>, 1993, 122(5 Pt 1):806-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/8496767/pubmed\" target=\"_blank\" id=\"8496767\">8496767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i>. 2010;115(2):168-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/19846889/pubmed\" target=\"_blank\" id=\"19846889\">19846889</a>]</span><span class=\"doi\">10.1182/blood-2009-06-225565</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"760656\"></a>Ridgway HB, Hansotia PL, Schorr WF. Relapsing polychondritis: unusual neurological findings and therapeutic efficacy of dapsone. <i>Arch Dermatology.</i> 1979;115(1):43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/760656 /pubmed\" target=\"_blank\" id=\"760656 \">760656 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7037880\"></a>Rogers RS 3rd, Seehafer JS, and Perry HO, &ldquo;Treatment of Cicatricial (Benign Mucous Membrane) Pemphigoid With Dapsone,&rdquo; <i>J Am Acad Dermatol</i>, 1982, 6(2):215-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/7037880/pubmed\" target=\"_blank\" id=\"7037880\">7037880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanders SW, Zone JJ, Foltz RL, et al, &quot;Hemolytic Anemia Induced by Dapsone Transmitted Through Breast Milk,&quot; <i>Ann Intern Med</i>, 1982, 96(4):465-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/7065565/pubmed\" target=\"_blank\" id=\"7065565\">7065565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stavola JJ and Noel GJ, &ldquo;Efficacy and Safety of Dapsone Prophylaxis Against <i>Pneumocystis carinii</i> Pneumonia in Human Immunodeficiency Virus-Infected Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1993, 12(8):644-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/8414776/pubmed\" target=\"_blank\" id=\"8414776\">8414776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thornton YS and Bowe ET, &quot;Neonatal Hyperbilirubinemia After Treatment of Maternal Leprosy,&quot; <i>South Med J</i>, 1989, 82(5):668.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/2717998 /pubmed\" target=\"_blank\" id=\"2717998 \">2717998 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services [HHS] Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed May 23, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. WHO Expert Committee on Leprosy. Eighth report. WHO technical report series 2012;968:1&ndash;61<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/22970604 /pubmed\" target=\"_blank\" id=\"22970604 \">22970604 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Werth VP, Fivenson D, Pandya AG, et al, &ldquo;Multicenter Randomized, Double-Blind, Placebo, Controlled Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris,&rdquo; <i>Arch Dermatol</i>, 2008, 144(1):25-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/18209165/pubmed\" target=\"_blank\" id=\"18209165\">18209165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuidema J, Hilbers-Modderman ES, and Merkus FW, &ldquo;Clinical Pharmacokinetics of Dapsone,&rdquo; <i>Clin Pharmacokinet</i>, 1986, 11(4):299-315.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-drug-information/abstract-text/3530584/pubmed\" target=\"_blank\" id=\"3530584\">3530584</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9096 Version 190.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8016738\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8015321\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8015320\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8015322\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8015323\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46564750\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8015379\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9490508\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8015365\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8015286\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475193\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8015264\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8015297\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8015294\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8015295\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8015301\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8015302\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8015289\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8015290\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8015293\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8015367\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8015309\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8015311\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322077\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390227\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9096|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dapsone-systemic-patient-drug-information\" class=\"drug drug_patient\">Dapsone (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=dapsone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Dapsone (systemic): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}